左卡尼汀治疗终末期肾病维持性血液透析患者心功能不全的价值分析

The value of L-carnitine in the treatment of end-stage renal disease patients with cardiac insufficiency

目的分析左卡尼汀治疗终末期肾病维持性血液透析患者心功能不全的价值。方法抽取我院2020年6月-2022年6月收治的52例终末期肾病维持性血液透析患者,将全部患者随机分为对照组(n=26)与观察组(n=26),对26例对照组患者实行常规治疗,对26例观察组患者实行左卡尼汀治疗,对比两组患者的治疗疗效、心功能指标检测结果、Hb、PVC指标、不良反应率。结果观察组患者治疗有效率为96.15%(25例),对照组患者治疗有效率为73.08%(19例),两组数据相比差别较大,观察组明显更优(P<0.05)。治疗后,观察组患者左室收缩末期内径、左室射血分数、左室舒张末期内径为(57.86土0.25)(49.55±0.36)(46.94±3.33),对照组患者为(64.58±0.34)(40.26±0.29)(54.35±3.11),两组数据相比差别较大,观察组明显更优(P<0.05)。治疗后,观察组患者Hb、PVC指标为(96.73±5.07)(35.73±3.97),对照组为(75.74±6.46)(22.58土3.43),两组数据相比差别较大,观察组明显更优(P<0.05)。观察组患者不良反应率为7.69%(2例),对照组患者不良反应率为34.62%(9例),两组数据相比差别较大,观察组明显更优(P<0.05)。结论治疗终末期肾病维持性血液透析患者,左卡尼汀治疗方式疗效显著,能切实改善患者心功能指标,贫血症状好转,治疗安全性更高,还可以切实提升生活质量水平,降低不良反应率,具有较高的临床应用推广价值。

Objective To analyze the value of L-carnitine in the treatment of cardiac insufficiency in endstage renal disease(ESRD-RRB-patients)undergoing maintenance hemodialysis.Methods From June 2020 to June 2022,52 patients with end-stage renal disease undergoing maintenance hemodialysis were randomly divided into control group(n=26)and observation group(n=26),26 patients in the control group were treated with conventional therapy and 26 patients in the observation group were treated with L-carnitine,the curative effect,cardiac function index,HB,PVC index and adverse reaction rate were compared between the two groups.Results The effective rate of the observation group was 96.15%(25)and that of the control group was 73.08%(19).There was a significant difference between the two groups.The observation group was superior to the control group(P<0.05).After treatment,the left ventricular end-systolic diameter,left ventricular ejection fraction and left ventricular end-diastolic diameter were(57.86±0.25),(49.55±0.36),(46.94±3.33)in the observation group and(64.58±0.34),(40.26±0.29),(54.35±3.11)(P<0.01)in the control group,the difference between the two groups was significant,the observation group was significantly better(P<0.05).After treatment,the indexes of HB and PVC were(96.73±5.07)(35.73±3.97)in the observation group and(75.74±6.46)(22.58±3.43)(P<0.05)in the control group.The adverse reaction rate was 7.69%(2)in the observation group and 34.62%(9)in the control group.There was a significant difference between the two groups.The observation group was superior to the control group(P<0.05).Conclusion L-carnitine is effective in the treatment of end-stage renal disease patients with maintenance hemodialysis,and it can improve cardiac function and anemia symptoms,it can also improve the quality of life,reduce the rate of adverse reactions,with high value of clinical application.